BU-NOT-SET

CONTACT US
The role of excipient selection in the development of orally disintegrating tablets
  • Drug product
Eyes
Insight
The outlook for a year of change
  • Industry trends
Eyes
Insight
Can oral solid dose keep its place as the leading dosage form?
  • Drug product
Eyes
Insight
Relocating API supply to avoid over-reliance
  • Drug substance
Eyes
Insight
Modified release fixed dose combination product with two poorly soluble drug substances
  • Drug product
pellets
Case study
Patient centricity during drug development and commercialisation
  • Drug product
Eyes
Insight
10 considerations to kick-start your drug development journey
  • Drug product
Eyes
Insight
Guidance for start-ups on drug development
  • Drug product
Eyes
Insight
Drug development for start-ups
  • Drug product
  • Drug substance
Test tubes
White paper
Fact sheet
  • Corporate
Licensing portfolio
Insight
  • Industry trends
Key trends in pharmaceutical outsourcing
Insight
  • Drug product
  • Industry trends
The latest trends and innovations in oral drug delivery
Insight
  • Corporate
Recipharm invests in African vaccine production
Insight
  • Drug product
  • Industry trends
The future of oral solid dose development and manufacturing
Report
  • Sustainability
Sustainability Report 2021
Insight
  • Corporate
Treating long-COVID with Erdosteine
Insight
  • Drug product
Three trends driving small molecule API market growth
Fact sheet
  • Drug product
Vaccine manufacturing